OBJECTIVE: Recently, variants in the TCF7L2 gene have been reported to be associated with type 2 diabetes across multiple Europid populations, but only one small sample of African-American type 2 diabetic patients has been examined. Our objective was to investigate the importance of TCF7L2 in a larger African-American case-control population. RESEARCH DESIGN AND METHODS: We investigated single nucleotide polymorphisms (SNPs) in six known type 2 diabetes genes in 577 African-American case subjects with type 2 diabetes enriched for nephropathy and 596 African-American control subjects. Additionally, we genotyped 70 ancestry-informative markers (AIMs) to apply adjustments for differences in ancestral proportions. RESULTS: The most significant associations were observed with TCF7L2 intron 3 SNPs rs7903146 (additive P = 4.10 x 10(-6), odds ratio [OR] 1.51; admixture-adjusted P(a) = 3.77 x 10(-6)) and rs7901695 (P = 0.001, OR 1.30; P(a) = 0.003). The 2-SNP haplotype containing these SNPs was also associated with type 2 diabetes (P = 3 x 10(-5)). Modest associations were also seen with TCF7L2 intron 4 SNPs rs7895340, rs11196205, and rs12255372 (0.01 < P < 0.05; 0.03 < P(a) < 0.08), as well as with ATP-sensitive inwardly rectifying potassium channel subunit Kir6.2 (KCNJ11) and hepatocyte nuclear factor 4-alpha (HNF4A) SNPs (0.01 < P < 0.05; 0.01 < P(a) < 0.41). No significant associations were detected with genotyped calpain 10 (CAPN10), peroxisome proliferator-activated receptor gamma (PPARG), and transcription factor 1 (TCF1) SNPs. CONCLUSIONS: This study indicates that variants in the TCF7L2 gene significantly contribute to diabetes susceptibility in African-American populations.
OBJECTIVE: Recently, variants in the TCF7L2 gene have been reported to be associated with type 2 diabetes across multiple Europid populations, but only one small sample of African-American type 2 diabeticpatients has been examined. Our objective was to investigate the importance of TCF7L2 in a larger African-American case-control population. RESEARCH DESIGN AND METHODS: We investigated single nucleotide polymorphisms (SNPs) in six known type 2 diabetes genes in 577 African-American case subjects with type 2 diabetes enriched for nephropathy and 596 African-American control subjects. Additionally, we genotyped 70 ancestry-informative markers (AIMs) to apply adjustments for differences in ancestral proportions. RESULTS: The most significant associations were observed with TCF7L2 intron 3 SNPs rs7903146 (additive P = 4.10 x 10(-6), odds ratio [OR] 1.51; admixture-adjusted P(a) = 3.77 x 10(-6)) and rs7901695 (P = 0.001, OR 1.30; P(a) = 0.003). The 2-SNP haplotype containing these SNPs was also associated with type 2 diabetes (P = 3 x 10(-5)). Modest associations were also seen with TCF7L2 intron 4 SNPs rs7895340, rs11196205, and rs12255372 (0.01 < P < 0.05; 0.03 < P(a) < 0.08), as well as with ATP-sensitive inwardly rectifying potassium channel subunit Kir6.2 (KCNJ11) and hepatocyte nuclear factor 4-alpha (HNF4A) SNPs (0.01 < P < 0.05; 0.01 < P(a) < 0.41). No significant associations were detected with genotyped calpain 10 (CAPN10), peroxisome proliferator-activated receptor gamma (PPARG), and transcription factor 1 (TCF1) SNPs. CONCLUSIONS: This study indicates that variants in the TCF7L2 gene significantly contribute to diabetes susceptibility in African-American populations.
Authors: Jacob DeMenna; Sobha Puppala; Geetha Chittoor; Jennifer Schneider; Joon Young Kim; Gabriel Q Shaibi; Lawrence J Mandarino; Ravindranath Duggirala; Dawn K Coletta Journal: Hum Hered Date: 2014-07-08 Impact factor: 0.444
Authors: Jason H Karnes; Yan Gong; Michael A Pacanowski; Caitrin W McDonough; Meghan J Arwood; Taimour Y Langaee; Carl J Pepine; Julie A Johnson; Rhonda M Cooper-Dehoff Journal: Pharmacogenet Genomics Date: 2013-12 Impact factor: 2.089
Authors: Hideki Kato; Antje Gruenwald; Jung Hee Suh; Jeffrey H Miner; Laura Barisoni-Thomas; Makoto M Taketo; Christian Faul; Sarah E Millar; Lawrence B Holzman; Katalin Susztak Journal: J Biol Chem Date: 2011-05-25 Impact factor: 5.157
Authors: Tennille S Leak; Josyf C Mychaleckyj; Shelly G Smith; Keith L Keene; Candace J Gordon; Pamela J Hicks; Barry I Freedman; Donald W Bowden; Michèle M Sale Journal: Hum Genet Date: 2008-06-17 Impact factor: 4.132
Authors: T S Leak; P S Perlegas; S G Smith; K L Keene; P J Hicks; C D Langefeld; J C Mychaleckyj; S S Rich; J K Kirk; B I Freedman; D W Bowden; M M Sale Journal: Ann Hum Genet Date: 2009-01-23 Impact factor: 1.670
Authors: Tennille S Leak; Carl D Langefeld; Keith L Keene; Carla J Gallagher; Lingyi Lu; Josyf C Mychaleckyj; Stephen S Rich; Barry I Freedman; Donald W Bowden; Michèle M Sale Journal: BMC Med Genet Date: 2010-02-08 Impact factor: 2.103
Authors: David J Friedman; Matthew E Talbert; Donald W Bowden; Barry I Freedman; Yves Mukanya; Keiichi Enjyoji; Simon C Robson Journal: Diabetes Date: 2008-12-18 Impact factor: 9.461